Ankyra is developing a platform to improve both the safety and efficacy of cytokine immunotherapies for cancer. Systemic dosing of these powerful immune stimulants is limited by broad immune activation and toxicity. We have developed methods to localize cytokines specifically and persistently when injected into tumor tissue, creating intense hot spots of inflammation that awaken an anti-tumor immune response. We are developing this approach for the treatment of solid tumors.

Founders

Tillman Gerngross, Ph.D.

Tillman Gerngross, Ph.D.

Co-Founder and Chairman of the Board

Karl Dane Wittrup, Ph.D.

Karl Dane Wittrup, Ph.D.

Co-founder

Darrell Irvine, Ph.D.

Darrell Irvine, Ph.D.

Co-founder

Team

Amarildes Marisa Andrade

Amarildes Marisa Andrade

Executive Assistant

Sailaja Battula, Ph.D.

Sailaja Battula, Ph.D.

Senior Director, Translational Research

Joseph Elassal M.D., MBA

Joseph Elassal M.D., MBA

Chief Medical Officer

Gail Iodice, BSN RN

Gail Iodice, BSN RN

Senior Director, Clinical Development

Howard L. Kaufman, M.D., FACS

Howard L. Kaufman, M.D., FACS

President and Chief Executive Officer

Cheryl K. Kent, MA

Cheryl K. Kent, MA

Senior Director, Clinical Operations

Michael Schmidt, Ph.D.

Michael Schmidt, Ph.D.

Chief Scientific Officer

Gregory Zarbis-Papastoitsis, Ph.D.

Gregory Zarbis-Papastoitsis, Ph.D.

EVP of Process and Manufacturing Sciences

Board of Directors

Tillman Gerngross, Ph.D.
Co-Founder of Adimab LLC
Terry McGuire
Partner, Polaris Partners
Ajay Royan
Partner, Mithril Capital
Phil Ferneau
Managing Partner, Borealis Ventures
Howard L. Kaufman, M.D., FACS
President and CEO, Ankyra Therapeutics

Scientific Advisory Board

Dr. Genevieve Boland, M.D, Ph.D.

Dr. Genevieve Boland, M.D, Ph.D.

Harvard Medical School, Massachusetts General Hospital

Dr. James L. Gulley, M.D., Ph.D.

Dr. James L. Gulley, M.D., Ph.D.

National Cancer Institute

Dr. John M. Kirkwood, M.D.

Dr. John M. Kirkwood, M.D.

University of Pittsburgh, UPMC Hillman Cancer Center

Dr. James J. Mulé, M.D.

Dr. James J. Mulé, M.D.

Moffitt Cancer Center

Dr. Jeffrey Schlom, Ph.D

Dr. Jeffrey Schlom, Ph.D

National Cancer Institute

Stefani Spranger, Ph.D.

Stefani Spranger, Ph.D.

Koch Institute for Integrative Cancer Research at MIT

Science

Pipeline

1

Veterinary Pipeline

2

Clinical Trials

Canine Trial

Evaluation of intratumoral alum-tethered canine interleukin-12 (cANK-101) in dogs with measurable oral malignant melanoma

For information about enrolling a patient in the Ankyra trial at Illinois, please contact:
Rebecca Kamerer, CVT, Clinical Trials Coordinator:
rmoss81@illinois.edu, 217-300-6453

Human Cancer Trials

Coming Soon

Culture

Our Commitment to Diversity and Inclusion

Ankyra Therapeutics strives to maintain an environment of strong employee engagement, which means that all employees must feel included and valued. We have sought to build and maintain a culture where inclusiveness and diversity is a reflex, and not a corporate initiative.

We have a deep sense of pride, passion, and belonging that transcends any individual position, business unit, language, or country; and we are unified in our shared commitment to excellence, innovation, and social responsibility. We understand that our success will be enhanced by including a diverse perspective which fosters different ideas, thoughts, and experiences to create a more creative work environment and to deliver better results.

Values

Scientific Integrity we value scientific rigor and honesty with a commitment to remain accountable, trustworthy and data-driven at all times.

Respect – we have developed a culture of respect to allow all people and perspectives to be communicated in an honest and open forum. We believe that respect for each other also leads to respect and improved communication with our key stakeholders, including investors, collaborators, consultants and patients. We also support an inclusive and diverse employee participation experience.

Innovation – we place a high emphasis on ‘out-of-the-box’ thinking and encourage new ideas and creative solutions to current challenges in drug development.

Teamwork – our culture is built around collaboration and teamwork as an important strategy for rapidly advancing scientific breakthroughs and clinical translation. We operate in a highly transparent, balanced and collegial working environment.

Passion –
we have brought together a diverse and highly skilled group of professionals who share a passion for improving the lives of patients with cancer.

Mission

The mission of Ankyra Therapeutics is to optimize the impact of anchored immunotherapy to improve the lives of patients with cancer.

Vision

Our vision is to be a leading authority in the delivery of intratumoral immunotherapy for patients with cancer.

83 Newbury Street • 4th Floor Boston, MA 02116
info@ankyratx.com